 Home > Active Ingredient News > Antitumor Therapy > Imfinzi in combination with tremelimumab shows OS-prolonging benefit in liver cancer

Imfinzi in combination with tremelimumab shows OS-prolonging benefit in liver cancer

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

primary peritoneal cancer

papillary bladder cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AstraZeneca recently announced more results from the Phase III HIMALAYA study, saying the addition of tremelimumab to its PD-L1 blocker Imfinzi (durvalumab) reduced the risk of death by 22% in patients with unresectable liver cancer

ASCO

The HIMALAYA study evaluated Imfinzi monotherapy and the STRIDE regimen, which consists of adding a single priming dose of tremelimumab to Imfinzi followed by Imfinzi every four weeks

AstraZeneca said the median survival time for patients on the STRIDE regimen was 16.

Tremelimumab is a human immunoglobulin (Ig) G2 monoclonal antibody directed against the human T cell receptor protein cytotoxic T lymphocyte-associated protein 4 (CTLA4) , with potential immune checkpoint inhibition and antitumor activity

immunity

Following a string of clinical failures with tremelimumab, AstraZeneca finally demonstrated last year that adding tremelimumab to Imfinzi+ chemotherapy significantly extended overall survival in lung cancer

lung cancer

Original source:

https://firstwordpharma.

https://firstwordpharma.
com/story/5482433 https://firstwordpharma.
com/story/5482433

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.